C4 Therapeutics To Present New Preclinical Data On Highly Selective Orally Bioavailable BiDAC Degraders At The American Association For Cancer Research Annual Meeting 2024
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the acceptance of two preclinical poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024 in San Diego, California.
Details of the posters are as follows:
Title: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis
Abstract Number: 1658
Session Date and Time: Monday April 8, 2024 9:00 AM - 12:30 PM PT
Location: Poster Section 14
Session Title: Cell Signaling Components as Therapeutic Targets
Presenter: Bridget Kreger, Ph.D., principal scientist, biology
Title: CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone
Abstract Number: 6064
Session Date and Time: Tuesday April 9, 2024 1:30 PM - 5:00 PM PT
Location: Poster Section 30
Session Title: Targeted Protein Degraders
Presenter: Laura Poling, Ph.D., director, biology
In November 2023, C4T made the strategic decision to discontinue clinical development of CFT8634 based on clinical data from the Phase 1 trial.